While decreasing intraocular stress stays the one confirmed solution to sluggish or halt illness development in glaucoma sufferers, a number of research recommend that life-style adjustments could have a constructive impression on outcomes as properly. In a current literature assessment, researchers from India explored the potential function of life-style modifications within the prevention and administration of the situation, notably as complementary methods alongside conventional IOP-lowering remedies. They discovered that bodily exercise and train, mindfulness, rest, optimized sleep hygiene and quitting smoking can meaningfully increase conventional glaucoma therapies. Their paper was printed in World Journal of Methodology.1
The results of varied life-style components—together with weight loss plan, bodily exercise, yoga practices, sleep posture and using dietary dietary supplements—on the event and development of glaucoma have been examined.
Physical exercise emerged as one of the crucial persistently helpful life-style parts. Acute cardio train (half-hour of reasonable treadmill strolling) transiently lowered IOP by as much as 3.5 mmHg. “Importantly, a 12-month supervised aerobic program yielded a sustained 1.5 mmHg IOP reduction and slowed RNFL thinning by nearly 45 percent compared to controls, suggesting durable structural protection,” the authors write of their paper. “Mechanistically, exercise augments optic nerve head perfusion, elevates endogenous neurotrophins such as BDNF and attenuates oxidative stress—factors implicated in glaucoma pathogenesis.” Incorporating common moderate-intensity cardio train into glaucoma administration plans not solely helps to regulate IOP, but in addition offers broader neuroprotective and cardiovascular advantages.
Mindfulness-based stress discount and sleep optimization demonstrated promising adjunctive advantages. Two randomized scientific trials of mindfulness-based stress discount reported 1.8 mmHg to 2.3 mmHg IOP reductions alongside 20- to 30-percent decreases in anxiousness scores, enhancements in vision-related high quality of life and downregulation of the stress biomarkers cortisol, interleukin-6 and tumor necrosis factor-alpha.
“These findings underscore the role of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in modulating IOP and retinal ganglion cell vulnerability,” the authors clarify of their research. “In sleep apnea cohorts, CPAP therapy correlated with 10 percent slower visual field deterioration over one year, suggesting nocturnal oxygenation influences optic nerve resilience.”
Previous research have reported that smoking cessation decreased the speed of visible area decline, a truth confirmed in these findings, because it was related to a 15 p.c slower charge of retinal nerve fiber layer thinning—implicating tobacco-induced vascular compromise and oxidative damage in glaucoma development.
The additive advantages of those life-style modifications could also be clinically significant along with established IOP-lowering medicines, lasers and surgical procedure, the authors conclude of their paper.
“A sustained 1 mmHg to 3 mmHg IOP reduction can reduce the risk of glaucoma progression by 10 to 20 percent, similar to an additional topical agent. Moreover, non-IOP-mediated neuroprotective effects—through enhanced perfusion, neurotrophin induction and inflammation control—address pathophysiologic pathways not targeted by current therapies.” The authors added that life-style interventions additionally enhance cardiovascular well being, scale back comorbidities and improve total high quality of life, a very salient consideration given the excessive prevalence of temper problems and remedy burden in glaucoma sufferers.”
1. Aggarwal S, Morya AK, Kaur R, et al. Role of life-style modifications in glaucoma: A scientific assessment. World J Methodol. March 20, 2026. [Epub ahead of print.]
Anti-VEGF Injection May Increase Cataract Risk
A current research printed in Ophthalmology on the affiliation between anti-VEGF injections and incidence of cataract surgical procedure has discovered that injection-receiving eyes are at better threat of later requiring surgical procedure, notably in older sufferers.1
“The direct relationship between anti-VEGF injections and cataract development,” say the authors of their paper on the work, “has not been clearly established,” prompting an exploration of how these components have an effect on each other. Patients have been chosen based mostly on the presence of phakic lens standing in each eyes, amounting to 603 sufferers in whole. Their info—recorded over 15 years, between 2010 and 2025—was obtained by means of digital medical data and adopted for a mean of 74 months to trace development. A complete of 79.6 p.c of the members had moist AMD, whereas 20.4 p.c offered with macular edema secondary to retinal vein occlusion; as well as, 225 sufferers had acquired cataract surgical procedure, amongst which 194 (32.2 p.c of the total pattern of 603) have been operated on in solely the injected eye, eight (1.3 p.c) within the non-injected eye and 23 (3.8 p.c) in each eyes.
Anti-VEGF injections have been both bevacizumab, ranibizumab, aflibercept or brolucizumab administered within the type of three loading doses a month, adopted by both an as-needed or treat-and-extend routine as per typical protocols. Patients who acquired cataract surgical procedure within the injected eyes did so at a virtually sixfold larger charge: 40.7 p.c prevalence charge after 10 years, contrasted with 7.2 p.c within the fellow, non-injected eye.
The authors conclude that “eyes receiving repeated intravitreal anti-VEGF therapy were at a significantly higher risk of cataract surgery than their fellow eyes,” emphasizing dose-response relationship as a major issue; they attributed this relationship to quite a lot of causes, with “inadvertent physical trauma to the lens or zonules during the injection procedure” enjoying a major function, in addition to intraocular irritation (uveitis). Chronic uveitis is broadly understood to be “a well-established risk factor for cataract development.”
Further analysis is important to grasp the extent of this relationship, although the authors’ current understanding of anti-VEGF injections’ correlation with cataract improvement and surgical procedure factors to potential flaws within the means of injection. Should this be the case, retina specialists ought to change into extra attentive to how they administer injections and modify accordingly.
1. Choi J, Choi E, Kang SW, et al. Impact of intravitreal anti-vascular endothelial development issue injections on cataract improvement. Ophthalmology. March 4, 2026. [Epub ahead of print].
Toric IOLs Stable for at Least Two Years Postop, Study Finds
Despite the recognition of toric intraocular lenses for corneal astigmatism, most research so far have targeted on early postoperative outcomes, leaving a spot within the literature on long-term rotational stability and reoperation charges. To examine, researchers not too long ago carried out a scientific assessment that decided these IOLs provide sturdy correction of astigmatism and wonderful rotational stability for as much as two years, together with a modest reoperation charge of lower than 1 p.c.1
A search of Ovid Embase and PubMed databases yielded 19 research that reported outcomes of toric IOL implantation at the least one 12 months after the process. The experiences encompassed a complete of 1,180 members and 1,564 eyes, with follow-up intervals averaging round 30 months. Patients with different ocular comorbidities have been excluded.
The evaluation reveals that the imply residual astigmatism decreased to
-0.65 D at one 12 months and to -0.80 D at two years—a significant discount from the preoperative common of
-2.17 D. Furthermore, the assessment documented a low IOL reoperation charge of solely 0.77 p.c, principally occurring inside the first 4 weeks post-surgery, which the researchers famous of their paper “reinforces the overall safety of the procedure.”
Stability was a key discovering, as the common rotation of the IOL was measured at 2.27 levels at one 12 months and barely elevated to 2.82 levels by two years. “This stability is a critical metric for both surgeons and patients, as it provides confidence for a durable correction,” the researchers clarify. There have been outliers, nevertheless; notably, most research that reported instances requiring surgical repositioning concerned sufferers with a excessive axial size (>25 mm), which the authors observe “highlights a potential risk factor for [clinicians] before counselling a patient with axial myopia for toric IOL implantation.”
The researchers acknowledge a number of limitations that would have an effect on their conclusions. Most included research have been uncontrolled cohorts and case sequence, doubtlessly introducing choice and efficiency biases. Significant scientific heterogeneity was additionally noticed, with follow-up durations starting from 12 to 96 months and inconsistent pre- and postoperative measurements, limiting evaluation of long-term tendencies past two years.
Overall, these findings underscore the efficacy and security of toric IOLs in astigmatism administration. “Toric IOL implantation delivers a significant, durable correction of astigmatism with a satisfactory rotational stability for up to two years and a low long-term reoperation rate,” the researchers conclude, whereas including, that future research with follow-up exceeding 5 years are warranted to elucidate even longer-term outcomes.”
1. Lam CCY, Tsang A, Mok E, et al. Long-term astigmatism discount with toric intraocular lenses – a scientific assessment. J Cataract Refract Surg. February 18, 2026. [Epub ahead of print].
Risk of Ischemic Optic Neuropathy with Semaglutide
Recent research have linked semaglutide, probably the most generally prescribed GLP-1 receptor agonist, with an elevated incidence of ischemic optic neuropathy. Using 31,774 semaglutide instances from the FDA Adverse Event Reporting System (2017 to 2024), researchers from Canada not too long ago evaluated formulation- and sex-specific associations with sufferers with diabetes and weight problems, with the strongest affiliation noticed for the weight-loss formulation of the drug Wegovy.1
Ozempic generated about seven occasions extra experiences than Wegovy, owing to its earlier approval. Despite this distinction in quantity, Wegovy confirmed the strongest disproportionality sign for ischemic optic neuropathy (reporting odds ratio [OR]=74.89) in contrast with Novo Nordisk diabetic drug Ozempic (reporting OR=18.81). Disproportionality displays relative reporting somewhat than incidence and could also be influenced by publicity, indication or media consideration.
Sex-stratified analyses confirmed larger odds in males, and multivariable regression confirmed better threat with Wegovy vs. Ozempic (adjusted OR=4.74), in addition to in males vs. ladies (adjusted OR=3.33).
Tirzepatide (Zepbound), a twin GLP-1/GIP agonist, confirmed a good security profile, with GIP agonism most likely buffering GLP-1-mediated fluid shifts, stabilizing vascular tone and lowering ischemic vulnerability.
“This may further lower non-arteritic anterior ischemic optic neuropathy (NAION) risk indirectly by improving sleep apnea and oxygenation through fat loss,” the researchers remark of their paper.
Because this drug confirmed no disproportionality sign for ischemic optic neuropathy, the research means that the danger of NAION could also be GLP-1-specific somewhat than purely metabolic. Although tirzepatide’s shorter availability (about three years vs. over seven years for semaglutide) limits publicity, the reproducible semaglutide sign highlights the necessity for individualized GLP-1 remedy and potential threat stratification.
1. Lakhani M, Al-Ani A, Popovic M, et al. Ischemic optic neuropathy with semaglutide: international observational evaluation of sex- and formulation-specific threat. Br J Ophthalmol. March 10, 2026. [Epub ahead of print].